Table 1.

Demographics and immune histories of the PARIS study participants

Seropositivity pre-vaccine	Yes	No	Total
	N = 183	N = 313	N = 496
Age
Mean – Avg (Std)	42 (11.7)	40 (11.6)	41 (11.6)
Range	21–77	22–74	21–77
Gender - N (%)
Female	118 (64%)	216 (69%)	334 (67%)
Male	61 (33%)	88 (28%)	149 (30%)
Missing/other	4 (2%)	9 (3%)	13 (3%)
Ancestry - N (%)
African American	15 (8%)	16 (5%)	31 (6%)
Asian	21 (11%)	50 (16%)	71 (14%)
White	104 (57%)	175 (56%)	279 (56%)
Missing/other	43 (23%)	72 (23%)	115 (23%)
Ethnicity - N (%)
Hispanic	31 (17%)	36 (12%)	67 (14%)
Non-Hispanic	133 (73%)	230 (73%)	363 (7%)
Missing/other	19 (10%)	47 (1%)	66 (13%)
Primary vaccine series
Moderna	35 (19%)	76 (24%)	111 (22%)
Pfizer	127 (69%)	215 (69%)	342 (69%)
Not received	15 (8%)	20 (6%)	35 (7%)
Other	5 (3%)	0 (0%)	5 (1%)
Unknown	1 (1%)	2 (1%)	3 (1%)
Vaccine dose 3 (%)
Moderna	29 (16%)	67 (21%)	96 (19%)
Pfizer	89 (49%)	174 (56%)	263 (53%)
Not received	64 (35%)	69 (22%)	133 (27%)
Other	0 (0%)	1 (<1%)	1 (<1%)
Unknown	1 (1%)	2 (1%)	3 (1%)
Vaccine dose 4 (%)
Moderna	1 (1%)	3 (1%)	4 (1%)
Moderna bivalent	3 (2%)	9 (3%)	12 (2%)
Pfizer	5 (3%)	16 (5%)	21 (4%)
Pfizer bivalent	16 (9%)	38 (12%)	54 (11%)
Bivalent unspecified	1 (1%)	3 (1%)	4 (1%)
Unknown	1 (1%)	1 (<1%)	2 (<1%)
Not received	156 (85%)	243 (78%)	399 (80%)
Vaccine dose 5
Moderna bivalent	0 (0%)	1 (<1%)	1 (<1%)
Pfizer bivalent	5 (3%)	9 (3%)	14 (3%)
Not received	178 (97%)	303 (97%)	481 (97%)
SARS-CoV-2 infections - N (%)
Never	0 (0%)	155 (50%)	155(31%)
Once	136 (74%)	137 (44%)	273 (55%)
Twice	45 (25%)	20 (6%)	65 (13%)
Thrice	2 (1%)	1 (<1%)	3 (1%)
Job description - N (%)
Clinician	52 (28%)	99 (32%)	151 (30%)
PA/Nursing	37 (20%)	84 (27%)	121 (24%)
PhD/Trainee	19 (10%)	47 (15%)	66 (13%)
Social worker	6 (3%)	2 (1%)	8 (2%)
Family member	11 (6%)	3 (1%)	14 (3%)
Midwife	2 (1%)	3 (1%)	5 (1%)
Other	52 (28%)	65 (21%)	117 (24%)
Missing	4 (2%)	10 (3%)	14 (3%)